S0883
柳氮磺胺吡啶
97.0-101.5%
别名:
2-羟基-5-\ { \ { 4-[（2-吡啶氨基）磺酰基]苯基}偶氮}苯甲酸, 5-[对-(2-吡啶胺磺酰基)苯]偶氮水杨酸, 柳氮磺胺吡啶
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C18H14N4O5S
化学文摘社编号:
分子量:
398.39
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
EC Number:
209-974-3
Beilstein/REAXYS Number:
356241
MDL number:
Quality Level
assay
97.0-101.5%
form
powder
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
mp
260-265 °C (dec.) (lit.)
application(s)
forensics and toxicology
pharmaceutical (small molecule)
mode of action
DNA synthesis | interferes, enzyme | inhibits
SMILES string
OC(=O)c1cc(ccc1O)\N=N\c2ccc(cc2)S(=O)(=O)Nc3ccccn3
InChI
1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+
InChI key
NCEXYHBECQHGNR-QZQOTICOSA-N
Gene Information
human ... ALOX5(240), PTGS1(5742), PTGS2(5743)
General description
柳氮磺胺吡啶(SSZ)属于磺胺类药物，可代谢为5-氨基水杨酸和磺胺吡啶。SSZ是抗菌剂（磺胺吡啶）和消炎剂（水杨酸）的反应产物。
化学结构：磺胺
Application
柳氮磺胺吡啶在临床研究中用作分析标准品：
此外，还可作为分析参考标准，以通过酶联免疫吸附试验(ELISA)和荧光分光度技术量化生物样本和水样中的分析物。
- 研究其对多发性硬化症(MS)患者的治疗潜力。
- 通过抑制试验动物大鼠骨关节炎进展相关的软骨退变和疼痛研究其作为抗关节炎药物的作用。
此外，还可作为分析参考标准，以通过酶联免疫吸附试验(ELISA)和荧光分光度技术量化生物样本和水样中的分析物。
有关合适仪器技术的更多信息，请参考产品的分析证书。如需进一步支持，请联系技术服务。
Still not finding the right product?
Explore all of our products under 柳氮磺胺吡啶
signalword
Danger
Hazard Classifications
Aquatic Chronic 2 - Carc. 2 - Repr. 2 - Resp. Sens. 1 - Skin Sens. 1
存储类别
11 - Combustible Solids
wgk
WGK 2
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Irene E van der Horst-Bruinsma et al.
Annals of the rheumatic diseases, 72(7), 1221-1224 (2012-12-25)
To examine the impact (if any) of gender on the clinical, functional and patient-reported outcomes of treatment using data pooled from four controlled clinical trials. Study data were pooled from four clinical control trials in which 1283 adult patients with
Maarten Boers et al.
Annals of the rheumatic diseases, 72(3), 406-409 (2012-11-17)
Treatment of rheumatoid arthritis (RA) with tumour necrosis factor (TNF) antagonists changes the relationship between disease activity and progression of radiological joint damage ('disconnect'): patients who have little or no response of disease activity still show reductions in damage progression.
M van den Broek et al.
Clinical and experimental rheumatology, 30(4 Suppl 73), S35-S38 (2012-10-20)
Targeted treatment is effective in the short term in achieving low disease activity or even remission in patients with rheumatoid arthritis (RA). The benefits of long-term targeted treatment are discussed based on the BeSt study results. The BeSt study has
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| S0883-100G | 04061833015247 |
| S0883-50G | 04061833015261 |
| S0883-10G | 04061836830915 |